RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE

被引：0
|
作者：
Novick, Diego [1 ]
Ascher-Svanum, Haya [2 ]
Bertsch, Jordan [3 ]
Detke, Holland C. [2 ]
McDonnell, David [2 ]
Maria Haro, Josep [3 ]
机构：
[1] Eli Lilly & Co, Windlesham, Surrey, England
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Univ Barcelona, Barcelona, Spain
来源：
SCHIZOPHRENIA RESEARCH | 2012年 / 136卷
关键词：
D O I：
10.1016/S0920-9964(12)71044-7
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
212
引用
收藏
页码：S357 / S357
页数：1
相关论文
共 50 条
  • [1] RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE
    Novick, D.
    Ascher-Svanum, H.
    Bertsch, J.
    Detke, H.
    Mcdonnell, D.
    Witte, M.
    Haro, J.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A288 - A289
  • [2] Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, Pierre-Michel
    Choukour, Moutaz
    Watson, Susan B.
    Brunner, Elizabeth
    Ascher-Svanum, Haya
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (04) : 426 - 434
  • [3] OPEN-LABEL COMPARISON OF OLANZAPINE LONG-ACTING INJECTION AND ORAL OLANZAPINE: A 2-YEAR, RANDOMIZED STUDY IN OUTPATIENTS WITH SCHIZOPHRENIA
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, P. M.
    Choukour, M.
    Watson, Susan B.
    Brunner, E.
    Ascher-Svanum, H.
    [J]. SCHIZOPHRENIA BULLETIN, 2011, 37 : 300 - 300
  • [4] Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study
    Detke, H.
    Weiden, P. J.
    Lambert, T.
    Llorca, P. M.
    Choukour, M.
    Watson, S. B.
    Brunner, E.
    Ascher-Svanum, H.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S464 - S464
  • [5] Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
    Ascher-Svanum, Haya
    Novick, Diego
    Maria Haro, Josep
    Bertsch, Jordan
    McDonnell, David
    Detke, Holland
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 1125 - 1131
  • [6] LONG-TERM FUNCTIONAL IMPROVEMENTS IN THE 2-YEAR TREATMENT OF SCHIZOPHRENIA OUTPATIENTS WITH OLANZAPINE LONG-ACTING INJECTION
    Ascher-Svanum, Haya
    Novick, Diego
    Haro, Josep M.
    Bertsch, Jordan
    McDonnell, David
    Detke, Holland
    [J]. SCHIZOPHRENIA RESEARCH, 2012, 136 : S165 - S165
  • [7] Switching forensic schizophrenia outpatients from long-acting injectable antipsychotics to olanzapine: An open-label naturalistic study
    Bourget, D
    Labelle, A
    Boulay, LJ
    Tessier, P
    Ellis, J
    [J]. SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 160 - 161
  • [8] Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine
    McDonnell, David P.
    Kryzhanovskaya, Ludmila A.
    Zhao, Fangyi
    Detke, Holland C.
    Feldman, Peter D.
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (06) : 422 - 433
  • [9] Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia
    Ascher-Svanum, H.
    Peng, X.
    Montgomery, W.
    Faries, D. E.
    Lawson, A. H.
    Witte, M. M.
    Novick, D.
    Jemiai, N.
    Perrin, E.
    McDonnell, D. P.
    [J]. EUROPEAN PSYCHIATRY, 2011, 26 (05) : 313 - 319
  • [10] Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: An open-label naturalistic pilot study
    Labelle, A
    Bourget, D
    Boulay, LJ
    Ellis, J
    Tessier, P
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (06) : 545 - 553
12345